Latest news in cancer
Stanford researchers modified anti-cancer CAR-T cells so they can be controlled with an oral drug
June 2022: According to the findings of a study that was just recently published by Stanford Medicine in mice, a cancer treatment that makes use of a...
New CAR T-cell therapy showed acceptable safety profile in solid tumors
April 2022: According to preliminary data from a phase I/II clinical trial that was presented during the AACR Annual Meeting 2022, which was held from April...
Korean homegrown CAR T-Cell therapy is on the way
Nov 2021: The first clinical trial of South Korea’s homegrown next-generation chimeric antigen receptor T (CAR-T) cell therapy, which is designed to...
Lisocabtagene maraleucel is approved by FDA for second-line treatment of large B-cell lymphoma
July 2022: Lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) has been approved by the Food and Drug Administration for adult patients with large...
Dabrafenib in combination with trametinib is approved by FDA for unresectable or metastatic solid tumors with BRAF V600E mutation
July 2022: Dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) received accelerated approval from the Food and Drug Administration for the...
All participants in a small cancer trial achieved complete remission
June 2022: A small study of rectal cancer patients yielded extraordinary results: 100 percent of the individuals were in remission. The results were published...
Tisagenlecleucel is approved by FDA for relapsed or refractory follicular lymphoma
June 2022: After two or more lines of systemic therapy, the FDA awarded tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) expedited approval...
Opdivo in combination with chemotherapy and Opdivo in combination with Yervoy is approved by FDA for first-line esophageal squamous cell carcinoma indications
June 2022: For the first-line therapy of individuals with advanced or metastatic esophageal squamous cell carcinoma (ESCC), the Food and Drug Administration...
Ivosidenib in combination with azacitidine is approved for newly diagnosed acute myeloid leukemia
June 2022: Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) in combination with azacitidine has been approved by the Food and Drug Administration for newly...
Azacitidine is approved by FDA for newly diagnosed juvenile myelomonocytic leukemia
June 2022: The FDA has approved the drug azacitidine (Vidaza, Celgene Corp.) for children with newly diagnosed juvenile myelomonocytic leukaemia (JMML). The...
New treatment identified for low grade and serous ovarian cancer
May 2022: Trametinib may become a new standard of care for recurring, low-grade serous ovarian cancer (Mekinist). According to study findings published in the...
Weight loss is linked to decreased risk of colon and rectal polyps
May 2022: According to study findings published February 1 in the Journal of the National Cancer Institute, overweight or obese adults who lose more than 5...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.